78.04
Schlusskurs vom Vortag:
$75.59
Offen:
$75.77
24-Stunden-Volumen:
1.62M
Relative Volume:
0.87
Marktkapitalisierung:
$15.11B
Einnahmen:
$4.41B
Nettoeinkommen (Verlust:
$21.27M
KGV:
243.88
EPS:
0.32
Netto-Cashflow:
$288.81M
1W Leistung:
+11.23%
1M Leistung:
+14.01%
6M Leistung:
+5.29%
1J Leistung:
+21.05%
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
INCY
Incyte Corp
|
78.04 | 14.76B | 4.41B | 21.27M | 288.81M | 0.32 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
571.54 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
419.56 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
690.32 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
304.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-08-01 | Eingeleitet | Barclays | Overweight |
2025-06-16 | Hochstufung | Stifel | Hold → Buy |
2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
2024-12-17 | Eingeleitet | UBS | Neutral |
2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
2024-09-18 | Herabstufung | Truist | Buy → Hold |
2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
2024-02-23 | Eingeleitet | Jefferies | Buy |
2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
2023-07-25 | Eingeleitet | Citigroup | Buy |
2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
2021-01-07 | Eingeleitet | Truist | Buy |
2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2020-03-24 | Fortgesetzt | William Blair | Outperform |
2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
2019-10-03 | Eingeleitet | Mizuho | Buy |
2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
2019-04-11 | Eingeleitet | Stifel | Hold |
2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America - The Manila Times
Incyte's (INCY) "Neutral" Rating Reiterated at UBS Group - MarketBeat
Is it the right time to buy Incyte Corporation stockUnlock powerful investment tools for free - Jammu Links News
What makes Incyte Corporation stock price move sharplyBuild wealth faster with expert stock picks - Jammu Links News
Barclays Initiates Incyte With Overweight Rating, $90 Price Target, Retail Finds Reason To Cheer - Stocktwits
Incyte's new CEO outlines growth plan as Jakafi patent cliff nears - MSN
Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News - GuruFocus
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday - Benzinga
Barclays initiates coverage on Incyte stock with Overweight rating By Investing.com - Investing.com Canada
Barclays initiates coverage on Incyte stock with Overweight rating - Investing.com
Incyte's Stock Price Target Raised by RBC Capital to $72.00 - AInvest
Incyte (INCY) Receives Overweight Rating and $90 Price Target fr - GuruFocus
Why is Incyte Corporation stock attracting strong analyst attentionBest Dividend Insights For Consistent Profits - Jammu Links News
Incyte’s Earnings Call: Strong Growth Amid Challenges - The Globe and Mail
Incyte stock price target raised to $72 from $68 at RBC Capital - Investing.com Canada
Incyte stock price target raised to $72 from $68 at RBC Capital By Investing.com - Investing.com South Africa
Incyte stock price target raised to $60 from $52 at BMO Capital - Investing.com Canada
Incyte stock price target raised to $60 from $52 at BMO Capital By Investing.com - Investing.com South Africa
Incyte Corporation (NASDAQ:INCY) Q2 2025 Earnings Call Transcript - Insider Monkey
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte: Q2 Earnings Snapshot - Huron Daily Tribune
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Incyte Corp (INCY) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Raises Its Outlook After Beating Expectations On Jakafi Sales - Finimize
Incyte rises on results beat, lifted Jakafi guidance - MSN
Incyte stock price target raised to $79 by Truist on strong Jakafi sales - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 - Investing.com Canada
Incyte stock price target raised to $89 from $86 at TD Cowen on strong Q2 By Investing.com - Investing.com South Africa
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte earnings beat by $0.17, revenue fell short of estimates - Investing.com
Incyte’s Blood Cancer Drug Sales Forecast Gets A Lift - Finimize
Celestica, Corning, And Incyte Impress With Upbeat Quarterly Results - Finimize
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail
Incyte lifts annual sales forecast for blood cancer drug after solid quarter - whbl.com
Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
Earnings call transcript: Incyte Q2 2025 reveals revenue miss, stock gains - Investing.com
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say - Nasdaq
Incyte Q2 Results Top Estimates - Nasdaq
Incyte Corp. Achieves Strong Financial Performance in Q2News and Statistics - IndexBox
Incyte Q2 2025 slides: revenue up 16%, raises guidance on strong product performance - Investing.com
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates - Nasdaq
Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Incyte misses Q2 earnings estimates, raises Jakafi guidance By Investing.com - Investing.com Canada
Incyte misses Q2 earnings estimates, raises Jakafi guidance - Investing.com
Incyte Corp Q2 2025 Earnings: EPS of $2.04 and Revenue of $1.216 Billion Surpass Estimates - GuruFocus
Incyte Reports 2025 Second Quarter Financial Results - TradingView
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Yahoo Finance
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):